Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects.

NCT02296320 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02296320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02296320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects.
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
October 10, 2014
Completion date
October 2, 2018
Enrollment
213 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcus aureus pneumonia